Physician profile
James Blair
NPI 1902885700
$11,102.12
in general payments reported to CMS, 2019-2025
56 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $1,332 · 2021: $1,902 · 2022: $1,715 · 2023: $1,796 · 2024: $1,803 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,792 · Travel and Lodging: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,791.60 |
| Travel and Lodging | $282.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,724.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,474.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $857.81 | 2021-2025 | |
| Lilly USA, LLC | $562.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $534.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $507.48 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $468.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $437.51 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $402.30 | 2019-2023 | |
| Integra Lifesciences Corporation | $282.19 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.16 | 2019-2025 | Ofev, Jardiance |
| Merck Sharp & Dohme LLC | $222.95 | 2019-2025 | Belsomra, Vaxelis, Gardasil 9 |
| Amarin Pharma, INC. | $202.77 | 2019-2022 | |
| Shockwave Medical, INC | $192.71 | 2021 | |
| Axsome Therapeutics, INC. | $183.19 | 2023-2025 | Auvelity |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.